Analysts at RBC Capital upgraded AVEO Pharmaceuticals, Inc. AVEO from Underperform to Sector Perform.
The price target for AVEO Pharmaceuticals has been raised from $2.00 to $3.00.
AVEO Pharmaceuticals shares have dropped 22.28% over the past 52 weeks, while the S&P 500 index has surged 10.34% in the same period.
AVEO Pharmaceuticals' shares climbed 14.67% to $1.72 in pre-market trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in